82 related articles for article (PubMed ID: 16270096)
1. EGFR inhibitors: what have we learned from the treatment of lung cancer?
Giaccone G; Rodriguez JA
Nat Clin Pract Oncol; 2005 Nov; 2(11):554-61. PubMed ID: 16270096
[TBL] [Abstract][Full Text] [Related]
2. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
4. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
5. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
[TBL] [Abstract][Full Text] [Related]
6. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
[TBL] [Abstract][Full Text] [Related]
7. EGFR FISH versus mutation: different tests, different end-points.
Cappuzzo F
Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
Blons H; Côté JF; Le Corre D; Riquet M; Fabre-Guilevin E; Laurent-Puig P; Danel C
Am J Surg Pathol; 2006 Oct; 30(10):1309-15. PubMed ID: 17001163
[TBL] [Abstract][Full Text] [Related]
9. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
[TBL] [Abstract][Full Text] [Related]
10. Impact of EGFR mutation analysis in non-small cell lung cancer.
Yamamoto H; Toyooka S; Mitsudomi T
Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
[TBL] [Abstract][Full Text] [Related]
11. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
13. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
Jänne PA
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
[TBL] [Abstract][Full Text] [Related]
14. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib.
Schwab R; Pinter F; Moldavy J; Papay J; Strausz J; Kopper L; Keri G; Pap A; Petak I; Oreskovich K; Mangel L
J Clin Oncol; 2005 Oct; 23(30):7736-8. PubMed ID: 16234532
[No Abstract] [Full Text] [Related]
15. EGFR mutations and the terminal respiratory unit.
Yatabe Y
Cancer Metastasis Rev; 2010 Mar; 29(1):23-36. PubMed ID: 20135199
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
Heuckmann JM; Rauh D; Thomas RK
J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
[No Abstract] [Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.
Bencardino K; Manzoni M; Delfanti S; Riccardi A; Danova M; Corazza GR
Intern Emerg Med; 2007 Mar; 2(1):3-12. PubMed ID: 17551677
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.
Camp ER; Summy J; Bauer TW; Liu W; Gallick GE; Ellis LM
Clin Cancer Res; 2005 Jan; 11(1):397-405. PubMed ID: 15671571
[TBL] [Abstract][Full Text] [Related]
19. High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand.
Sriuranpong V; Chantranuwat C; Huapai N; Chalermchai T; Leungtaweeboon K; Lertsanguansinchai P; Voravud N; Mutirangura A
Cancer Lett; 2006 Aug; 239(2):292-7. PubMed ID: 16243431
[TBL] [Abstract][Full Text] [Related]
20. A cautionary lesson on the use of targeted methods for EGFR mutation analysis: a case report.
Walsh K; Wallace WA; Butler R; Mackean MJ; Harrison DJ; Stirling D; Oniscu A
J Clin Pathol; 2014 Aug; 67(8):734-5. PubMed ID: 24811487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]